bupropion has been researched along with Bulimia in 6 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Bulimia: Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as ox hunger.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women." | 9.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
| "In a placebo-controlled, double-blind study of the unique antidepressant agent bupropion in the treatment of nondepressed subjects with bulimia (bupropion group, N = 55; placebo group, N = 26), we found the drug significantly superior to placebo in reducing episodes of binge eating and purging." | 9.06 | Treatment of bulimia with bupropion: a multicenter controlled trial. ( Ascher, J; Cato, A; Ferguson, JM; Horne, RL; Hudson, JI; Lineberry, CG; Pope, HG, 1988) |
| " The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women." | 5.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
| "In a placebo-controlled, double-blind study of the unique antidepressant agent bupropion in the treatment of nondepressed subjects with bulimia (bupropion group, N = 55; placebo group, N = 26), we found the drug significantly superior to placebo in reducing episodes of binge eating and purging." | 5.06 | Treatment of bulimia with bupropion: a multicenter controlled trial. ( Ascher, J; Cato, A; Ferguson, JM; Horne, RL; Hudson, JI; Lineberry, CG; Pope, HG, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| White, MA | 1 |
| Grilo, CM | 1 |
| Swartz, CM | 1 |
| Gelenberg, AJ | 1 |
| Hahn, WK | 1 |
| Hudson, JI | 2 |
| Pope, HG | 2 |
| Horne, RL | 1 |
| Ferguson, JM | 1 |
| Lineberry, CG | 1 |
| Ascher, J | 1 |
| Cato, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder[NCT00414167] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00414167)
Timeframe: One week (at post treatment)
| Intervention | episodes/week (Mean) |
|---|---|
| Bupropion | 0.8 |
| Placebo | 1.0 |
Percent loss in Body Mass Index (NCT00414167)
Timeframe: 8 weeks (baseline and 8 weeks)
| Intervention | Percent loss (Mean) |
|---|---|
| Bupropion | 1.8 |
| Placebo | 0.6 |
2 trials available for bupropion and Bulimia
| Article | Year |
|---|---|
Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Body Mass Index; Bulimia; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; | 2013 |
Treatment of bulimia with bupropion: a multicenter controlled trial.
Topics: Adolescent; Adult; Ambulatory Care; Bulimia; Bupropion; Clinical Trials as Topic; Double-Blind Metho | 1988 |
4 other studies available for bupropion and Bulimia
| Article | Year |
|---|---|
Advancing age may inhibit antidepressant-induced seizure.
Topics: Age Factors; Bulimia; Bupropion; Humans; Middle Aged; Seizures | 1993 |
Imperfect drugs in an imperfect world.
Topics: Bulimia; Bupropion; Clinical Trials as Topic; Clozapine; Depressive Disorder; Humans; Nomifensine; P | 1992 |
Therapeutic effectiveness of bupropion for bulimia: a possible artifact.
Topics: Bulimia; Bupropion; Humans; Placebos; Propiophenones; Research Design; Statistics as Topic | 1989 |
Newer antidepressants in the treatment of bulimia nervosa.
Topics: Antidepressive Agents; Bulimia; Bupropion; Humans; Lithium; Lithium Carbonate; Nomifensine; Propioph | 1987 |